A study was conducted by The London School of Hygiene & Tropical Medicine (LSHTM) in 2019 to assess the Value of Human Papillomavirus Vaccination in Gavi-eligible low-income and middle-income countries. The purpose of the study was to prevent the danger of blanket recommendations made by international organisations that can lead to the adoption of healthcare interventions that are not cost effective in some countries.
The main study findings implied that at Gavi negotiation prices, HPV vaccination offers positive net health benefits in most of the Gavi-eligible countries included in the study. It would also largely contribute to decrease the burden of disability-adjusted life years for its patients.
The main study findings implied that Gavi’s negotiations for countries eligible for its support have succeeded in making adhering to the WHO guidance around HPV vaccination a beneficial aim for most countries. They also determined that calculating the prices using the methods mentioned, which account for country-specific health opportunity costs, will offer an opportunity to ensure that all countries can benefit from adopting HPV vaccination or other recommendations made by global bodies.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.
